Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996018292 - CONTROLLING DONOR BLOOD CHARACTERISTICS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

WE CLAIM;
1. A primary anticoagulant preparation for addition to a human blood sample unit intended for separation into a human blood platelet preparation comprising: a calcium ion chelating agent-type anticoagulant including citric acid and sodium citrate wherein the ratio of citric acid to total citrate is greater than about 30% by equivalent weight, said primary anticoagulant being added to a blood donation unit such that upon collection of the unit of blood, a resulting collected blood/anticoagulant mixture contains a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20 mM, and an initial pH of less than about 6.75.
2. A primary anticoagulant preparation as in Claim 1 wherein the calcium ion chelating agent-type anticoagulant is ACD-A.
3. A primary anticoagulant preparation as in Claim 1 wherein the calcium ion chelating agent-type anticoagulant is CPD.
4. A primary anticoagulant preparation as in Claim 1 wherein the calcium ion chelating agent-type anticoagulant includes citric acid and trisodium citrate.
5. A primary anticoagulant preparation as in Claim 1 wherein the total citrate concentration is between about 5.0 mM to about 20 mM of citrate.
6. A primary anticoagulant preparation as in Claim 1 wherein the total citrate concentration is between from about 7.0 mM to about 18 mM citrate.
7. A primary anticoagulant preparation as in Claim 1 wherein the citric acid concentration is greater than or equal to about 7.0 mM.

8. A primary anticoagulant preparation as in Claim 1 wherein the level of anticoagulant to whole blood in the resulting mixture is from about l: 6 to about 1:14 by volume.
9. An intermediate blood product useful for making improved platelet preparations on further processing, the intermediate blood product comprising:
an admixture of freshly collected human blood and an anticoagulant composition including citric acid and sodium-citrate, the admixture having a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20.0 mM and an pH of less than about 6.75.
10. A method of collecting human blood for preparing improved platelet preparations therefrom comprising the steps of:
introducing an anticoagulant preparation to a human blood sample being collected in a collection set adjacent a phlebotomy needle, the anticoagulant preparation being a solution including citric acid and sodium citrate wherein the ratio of citric acid to total citrate is greater than about 30% by equivalent weight, the anticoagulant being introduced at rate sufficient to provide a resulting collected blood anticoagulant mixture containing a citric acid concentration of greater than about 50 mM, a total citrate concentration of less than about 20.0 mM and an initial pH of less than about 6.75.
11. A method as in Claim 10 wherein the anticoagulant is introduced at a rate sufficient to provide a resulting collected blood/anticoagulant mixture having a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20.0 mM and an initial pH of less than about 6.75.

12. A method as in Claim 10 wherein the anticoagulant is introduced at a rate sufficient to provide a resulting collected blood/anticoagulant concentration of greater than or equal to about 7.0 mM and a total citrate concentration of about 7.0 mM to about 18.0 mM.
13. A method as defined in Claim 10 wherein the anticoagulant is introduced at a rate of whole blood:anticoagulant preparation of from about 6:1 to about 14:1.
14. A method as in Claim 10 wherein the anticoagulant preparation is introduced through a tubing junction provided in the collection set.
15. A method as in Claim 10 wherein the anticoagulant preparation is introduced by flowing it into collection tubing provided in the collection set.
16. A method as in Claim 10 wherein the anticoagulant preparation is introduced by pumping it into collection tubing provided in the collection set.
17. A method as in Claim 10 further comprising the step of: subjecting the resulting collected blood/anticoagulant mixture to blood separation procedures to provide a platelet product selected from the group consisting of platelet-rich plasma products and platelet-concentrate products.
18. A method as in Claim 10 further comprising the step of subjecting the resulting collected blood/anticoagulant mixture to automated blood separation procedures to provide a platelet concentrate product.
19. A method as in Claim 10 further comprising the step of subjecting the resulting collected blood/anticoagulant mixture to centrifugation separation processing to provide a platelet product selected from platelet-rich plasma and platelet-concentrate products.

20. A method of human blood platelet preparation to improve platelet storage comprising:
collecting whole blood into a primary anticoagu-lant formulation to form an anticoagulated blood mixture, the anticoagulant preparation including citric acid and trisodium citrate and the ratio of citric acid to total citrate being greater than about 30%, the anticoagulated blood mixture having a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20 mM, and an initial pH of less than about 6.75.